The emergence of modern photocatalysis, characterized by mildness and selectivity, has
significantly spurred innovative late-stage C–H functionalization approaches that make use …

Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

In the pursuit of new pharmaceuticals and agrochemicals, chemists in the life science
industry require access to mild and robust synthetic methodologies to systematically modify …

As one of the most successful therapeutic target families, G protein-coupled receptors
(GPCRs) have experienced a transformation from random ligand screening to knowledge …

Transcription factors (TFs) represent key biological players in diseases including cancer,
autoimmunity, diabetes and cardiovascular disease. However, outside nuclear receptors …

DNA-encoded chemical library (DECL) technology is used by the pharmaceutical industry to
discover small molecules capable of modulating biologically relevant targets. DECL …

Targeted protein degradation (TPD) has emerged as an exciting new era in chemical
biology and drug discovery. PROteolysis TArgeting Chimera (PROTAC) technology targets …

Despite intense interest in expanding chemical space, libraries containing hundreds-of-
millions to billions of diverse molecules have remained inaccessible. Here we investigate …

Cell–cell interactions in the central nervous system play important roles in neurologic
diseases. However, little is known about the specific molecular pathways involved, and …

Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …